
- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
ABSTRACT BACKGROUND: Telomeres, located at chromosome ends, are progressively shortened during each cell cycle by replication-dependent loss of DNA termini. Although maintenance of telomere
length is critical for cell-replicative potential and tumourigenesis, the erosion of telomeres can lead to genetic instability, a pivotal mechanism in the neoplastic process. PATIENTS AND
METHODS: A total of 118 colorectal cancer (CRC) samples (53 right-colon, 30 left-colon, and 35 rectal tumours) and corresponding adjacent non-cancerous tissues were evaluated for telomere
length, p53 mutation, and microsatellite instability (MSI). Telomere length was estimated by real-time PCR. RESULTS: Telomeres were significantly shorter in CRCs than in adjacent tissues,
regardless of tumour stage and grade, site, or genetic alterations (_P_<0.0001). Moreover, in normal tissues, but not in tumours, telomere length inversely correlated with age (_r_=−0.24,
_P_=0.017). Telomere length in CRCs did not differ with tumour progression or p53 status; however, in CRCs carrying the wild-type p53, telomeres were significantly shorter in tumours with
MSI than in those with stable microsatellites (_P_=0.027). Furthermore, telomere length differed according to tumour location, being longer in rectal cancers (_P_=0.03). CONCLUSIONS: These
findings suggest that telomere shortening is a key initial event in colorectal carcinogenesis. The extent of telomere erosion is related to tumour origin site and may be influenced by the
mismatch repair pathway. SIMILAR CONTENT BEING VIEWED BY OTHERS THE DYNAMICS OF TELOMERE LENGTH IN PRIMARY AND METASTATIC COLORECTAL CANCER LESIONS Article Open access 05 June 2023 THE
TELOMERE LENGTH LANDSCAPE OF PROSTATE CANCER Article Open access 25 November 2021 TELOMERE LENGTH WAS ASSOCIATED WITH GRADE AND PATHOLOGICAL FEATURES OF MENINGIOMA Article Open access 12
April 2022 MAIN Colorectal cancers (CRCs) encompass a heterogeneous complex of diseases differing in molecular pathways and biological characteristics, arising through a multistep
carcinogenic process, of which several genetic and epigenetic events have been characterised. There are at least two major pathways by which molecular events can lead to CRC: loss of
heterozygosity with chromosomal instability, and a deficient DNA mismatch repair pathway with microsatellite instability (MSI) (Grady and Carethers, 2008; Ogino and Goel, 2008; Koopman et
al, 2009). Although _p53_ and _K-ras_ genes are known to be involved in chromosomal instability-associated carcinogenesis, MSI is frequently associated with the CpG island methylator
phenotype (Barault et al, 2008). These two pathways are known to have a different origin and clinical outcome; right-sided proximal colon tumours are often MSI-associated lesions and have a
better prognosis than left-sided distal tumours (Iacopetta, 2002; Gervaz et al, 2004; Walther et al, 2008). Rectal tumours are thought to arise through mechanisms similar to left-colon
cancers; recently, it has been proposed that they constitute a third entity displaying specific characteristics (Li and Lai, 2009). Telomere dysfunction has emerged as having a causative
role in carcinogenesis by promoting genetic instability. Indeed, telomeres are specialised DNA structures located at the end of chromosomes; they are composed of (TTAGGG)_n_ tandem repeats
and are essential for stabilising chromosomes by protecting them from end-to-end fusion and DNA degradation. Telomeres are progressively shortened during each cell-replication cycle because
of end-replication problems of DNA polymerase, and telomere shortening induces somatic cells to undergo senescence and apoptosis (reviewed in Blackburn et al, 2006). Further erosion of
telomeres may impair their function in protecting chromosome ends, resulting in genetic instability. Although maintenance of telomere length by reverse transcriptase telomerase (hTERT) is
critical to preserving the replicative potential of cancer cells (Hiyama and Hiyama, 2007; Artandi and DePinho, 2010), telomere erosion has been proposed to have two conflicting roles:
tumour suppression and genetic instability, a key event in the initiation of carcinogenesis (Hackett and Greider, 2002; Meeker et al, 2004; Perera et al, 2008). The role of telomere
dysfunction in colorectal carcinogenesis is still largely undefined. Several studies demonstrated that telomeres were shorter in CRCs than in adjacent normal mucosa (Hastie et al, 1990;
Takagi et al, 1999; Gertler et al, 2004; Garcia-Aranda et al, 2006), but this finding was not confirmed by other studies (Katayama et al, 1999; O'Sullivan et al, 2006). Telomeres were
also found to be significantly shorter in high-grade dysplastic lesions (Raynaud et al, 2008) and large adenomas (O'Sullivan et al, 2006) than in normal adjacent mucosa; subsequent
activation of telomerase may explain the increase of telomere length from preneoplastic lesions to invasive carcinoma (Raynaud et al, 2008). However, the relationship between telomere length
and tumour progression remains to be assessed. Moreover, few studies have addressed the relationship of telomere length with the site of tumour origin and/or molecular pathways of
colorectal carcinogenesis. The suggestion that right-colon cancers have shorter telomeres than tumours arising in other sites (Takagi et al, 1999; Garcia-Aranda et al, 2006) has not been
confirmed in other studies (Engelhardt et al, 1997; Gertler et al, 2004). One study suggested that telomeres were shorter in MSI tumours than in cancers with stable microsatellites (MSS)
(Takagi et al, 2000), but a relationship between telomere length and markers of chromosome instability in MSS tumours has not been established yet. Telomere length has traditionally been
estimated by Southern blotting using enzymes with restriction sites in subtelomeric DNA. However, the large amounts of DNA required by this method limit its use in many biological samples.
Using a real-time quantitative PCR method, we analysed telomere length in a large series of CRCs and we then determined the association of this parameter with tumour stage, location, and
markers of genetic instability. PATIENTS AND METHODS PATIENTS For this study, 118 cases were selected from patients with a histopathological confirmation of CRC who underwent surgical
resection at a single institution. The criteria of selection were the availability of adjacent non-cancerous mucosa and data on _p53_ gene mutation and MSI status (_n_=193). In all, 28
tumour samples (14.5%) were found to have a high degree of MSI (MSI-H); this percentage reflected that reported in literature (Kim et al, 2007; Ogino et al, 2009) and all 28 were included in
this study. In agreement with previous reports (Kim et al, 2007; Grady and Carethers, 2008; Ogino et al, 2009), most of the MSI-H samples (24 of 28) had the wild-type _p53_ gene. An equal
number of age-matched MSS tumours were selected with the wild-type (_n_=45) or mutated (_P_=45) _p53_ gene. The median age of selected patients was 65 years (range 41–82 years); 49 were
women and 69 were men. According to the American Joint Committee on Cancer staging (Greene et al, 2002), 23 tumours were classified as stage I (T1–T2, N0, M0), 37 as stage II (T3–T4, N0,
M0), 29 as stage III (any T, N1–N2, M0), and 29 as stage IV (any T, any N, M1). Moreover, 18 tumours were classified as grade 1, 78 as grade 2, 17 as grade 3, and 5 were mucinous. Grading
was assessed independently by two pathologists. Tumours were located in the right colon in 53 cases (44.9%), in the left colon in 30 cases (25.4%), and in the rectum in 35 cases (29.7%). At
the time of sampling, each patient signed the informed consent form approving the use of his or her biological samples for research purposes. The study was approved by the local ethical
committee. SAMPLES Tissues specimens were obtained at the time of surgery, immediately shock frozen in liquid nitrogen, and stored at −80°C until use. Cryostat sections of 6 _μ_m thickness
from each tissue sample were prepared using a 1720 Digital cryostat (Leitz, Germany). One section of each sample was stained with haematoxylin–eosin for histopathology. All tumour samples
analysed for telomere length contained >80% tumour cells. DNA was extracted by the standard phenol/chloroform method from frozen tissues. TELOMERE LENGTH MEASUREMENT BY QUANTITATIVE
REAL-TIME PCR Telomere length was determined using real-time PCR (Cawthon, 2002; O'Callaghan et al, 2008) with minor modifications. Two PCRs were performed for each sample, one to
determine the cycle threshold (_C_t) value for telomere (T) amplification and the other to determine the _C_t value for the amplification of a single-copy (S) control gene (acidic ribosomal
protein P0, RPLP0). The primer sequences for telomere amplification were TEL1B 5′-CGGTTTGTTTGGGTTTGGGTTTGGGTTTGGGTTTGGGTT-3′ and TEL2B 5′-GGCTTGCCTTACCCTTACCCTTACCCTTACCCTTACCCT-3′
(O'Callaghan et al, 2008) and those for RPLP0 amplification were RPLP01 5′-CAGCAAGTGGGAAGGTGTAATCC-3′ and RPLP02 5′-CCCATTCTATCATCAACGGGTACAA-3′ (Boulay et al, 1999). Each PCR reaction
was performed using a 10 _μ_l sample (1 ng of DNA per _μ_l) and a 40 _μ_l mixture containing 1.25 U AmpliTaq Gold DNA polymerase (Applied Biosystems, Foster City, CA, USA), 150 nM 6-ROX, 0.2
× SYBRGreen I nucleic acid stain 10 000 × (Invitrogen, Milan, Italy), 50 mM KCl, 2 mM MgCl2, 0.2 mM of each deoxynucleoside triphosphate (Applied Biosystems), 5 mM dithiothreitol, 1%
dimethyl sulphoxide, and 15 mM Tris–HCl pH 8.0, as well as primer pair TEL1B (300 nM) and TEL2B (900 nM) or primer pair RPL01 (300 nM) and RPL02 (500 nM). A reference curve was generated at
each PCR run, consisting of reference DNA from the RAJI cell line (Nishikura et al, 1985) serially diluted from 10 to 0.41 ng _μ_l−1. All real-time PCR reactions were carried out using the
ABI Prism 7900 HT Sequence Detection System (Applied Biosystems). Telomere and RPLP0 sequences were amplified using the following conditions: 95°C for 10 min to activate the AmpliTaq Gold
DNA polymerase, and then 25 cycles each at 95°C for 15 s and 54°C for 2 min for telomere; 40 cycles each at 95°C for 15 s and 58°C for 1 min for RPLP0. ABI Prism software version 2.3 was
used for analysis. Intra- and inter-assay reproducibility of both telomere and RPL0 PCR results was evaluated initially in a series of experiments using dilutions of the reference curve. The
s.d. of _C_t values was ⩽0.189 (% coefficient of variation ⩽1.13) in six replicates of samples amplified in the same PCR run, and ⩽0.251 (% coefficient of variation ⩽1.58) among mean values
of triplicates in different PCR runs. Both reference and sample DNAs were analysed in duplicate. Variation of _C_t values in the sample was ⩽0.3 _C_t (s.d. ⩽0.212; % coefficient of
variation ⩽1.25) in both telomere and RPL0 PCR runs. Mean _C_t values were used to calculate the relative telomere length using the telomere/single-copy-gene ratio (T/S) according to the
formula: Δ_C_tsample=_C_ttelomere−_C_tcontrol, ΔΔ_C_t=Δ_C_tsample−Δ_C_treference curve (where Δ_C_treference curve=_C_ttelomere−_C_tcontrol ) and then T/S=2−ΔΔ_C_t (Cawthon 2002;
O'Callaghan et al, 2008). TELOMERE LENGTH MEASUREMENT BY SOUTHERN BLOTTING In an initial series of samples, telomere length was also determined by Southern blotting. Aliquots of 5 _μ_g
DNA were digested with _Hinf_1 and _Rsa_1 restriction enzymes (20 U each) for 3 h at 37°C. Digested telomere restriction fragments were separated by 0.8% agarose gel electrophoresis. Gels
were transferred to a positively charged nylon membrane and were UV cross-linked for 5 min. Hybridisation was performed with the TeloTAGG telomere length assay kit (Roche Diagnostics,
Mannheim, Germany) according to the manufacturer's recommendations. Briefly, filters were hybridised with a digoxigenin (DIG)-labelled telomere-specific probe for 3 h at 42°C, washed
twice, and then incubated with a DIG-specific antibody coupled to alkaline phosphatase (AP) for 30 min. Hybridisation was finally visualised using AP-metabolising CDP-Star (Disodium
2-chloro-5-(4-methoxyspiro {1,2-dioxetane-3,2'-(5'-chloro)tricyclo-[3.3.1.13,7]decan}-4-yl)-1-phenyl phosphate; Sigma, St Louis, MO, USA), a highly sensitive chemiluminescent
substrate. Membranes were scanned and telomere lengths were estimated by densitomer analysis (Gel Doc 100, Biorad, Milan, Italy). QUANTIFICATION OF HTERT TRANSCRIPTS Extraction of RNA from
CRC samples and reverse transcription of RNA into cDNA were carried out as previously described (Terrin et al, 2008). The quantification of all hTERT transcripts (hTERT-AT) in CRC samples
was carried out by real-time PCR, exactly as previously described (Terrin et al, 2007, 2008), and normalised for 103 copies of the housekeeping hypoxanthine guanine phosphoribosyl
transferase 1 (_HPRT1_) gene (Terrin et al, 2008). P53 AND MSI ANALYSES _P53_ gene mutations were detected by PCR single-strand conformational polymorphism (SSCP) analysis of exons 4–8, and
DNA sequencing of samples with abnormal SSCP results (Bertorelle et al, 1995). The MSI status was determined by analysing five microsatellites of the Bethesda recommended panel (BAT-25,
BAT-26, D2S123, D5S346, and D17S250) (Pucciarelli et al, 2003), and defining high MSI (MSI-H) tumours as those with two or more altered markers (Boland et al, 1998). STATISTICAL ANALYSIS
Comparisons of telomere length in normal and neoplastic tissues according to gender, site of disease, tumour stage and grade, MSI and p53 status were performed using the Kruskal–Wallis test.
The relationship between telomere length and age was explored with the Spearman's rank correlation coefficient. The diagnostic performance of T/S values was evaluated using a
receiver-operating characteristic curve; the cutoff point corresponding to the maximum Younden index was selected to better discriminate between normal and cancerous tissue. Results were
reported with their 95% confidence intervals (CI). Multiple linear regression analyses were used to determine the adjusted association of telomere length with tumour location, age, p53 and
MSI status. All _P_-values were two-sided, and _P_-value of <0.05 was considered statistically significant. Statistical analyses were performed using SAS stastical software (SAS
Institute, Cary, NC, USA). RESULTS TELOMERE LENGTH IN CANCER TISSUES AND ADJACENT NON-CANCEROUS MUCOSA In 118 tumour samples and the corresponding adjacent non-cancerous tissues, telomere
length was determined by real-time PCR. For 42 cases, telomere length was also assessed by Southern blotting. A significant linear correlation was found between the T/S values provided by
real-time PCR and the telomere length estimated by Southern blot (_r_s=0.860, 95% CI 0.77–0.92, _P_<0.0001, Figure 1). Overall, the median level of T/S values in cancer samples was 0.64
(interquartile range (IQR), 0.47–0.99), lower than that estimated in adjacent mucosa (median 1.84(1.47–2.63); _P_<0.0001) (Figure 2A). Conversion of T/S values in Kb, using the
relationship shown in Figure 1, indicated that telomere length varied from 3.38 to 7.44 Kb with a median (IQR) of 4.10 (3.83–4.64) Kb in tumours, and from 3.61 to 11.55 Kb with a median of
5.93(5.36–7.15) Kb in normal tissues. Telomere lengths were shorter in cancers than in adjacent non-cancerous mucosa for all tumour stages (_P_<0.0001; Figure 2B) and grades (median (IQR)
0.63(0.47–0.97) _vs_ 2.04(1.40–2.41), 0.67(0.46–1.02) _vs_ 1.87(1.49–2.78), and 0.59(0.45–0.78) _vs_ 1.68(1.45–2.21) for grades 1, 2, and 3, respectively; tumours _vs_ normal tissues
_P_<0.0001). Although no correlation was found between age and telomere length in cancers, telomere length in normal tissues inversely correlated with age (_r_=−0.24, 95% CI −0.42 −0.05,
_P_=0.017; Figure 2C). A patient-by-patient comparison of matched tissue samples showed that all but four cases had longer telomeres in non-cancerous mucosa than in CRC samples with a median
difference of 1.22 (0.61–1.81); these differences inversely correlated with age (_r_=−0.23, 95% CI −0.41–0.04, _P_=0.023). From the receiver-operating characteristic curve analysis, the T/S
value that best discriminated between the telomere length of neoplastic and normal tissues was 1.14. By using this cutoff value, sensitivity and specificity of the assay for
cancer-associated telomere were 83% (95% CI 75–90%) and 92% (95% CI 85–96%), respectively (Figure 2D). RELATIONSHIP BETWEEN TELOMERE LENGTH AND TUMOUR CHARACTERISTICS Telomere lengths did
not significantly differ with tumour stage. Median (IQR) T/S values were 0.66 (0.56–0.66), 0.69(0.49–0.93), 0.55(0.39–1.02), and 0.64 (0.51–0.98) in tumour stages I, II, III, and IV,
respectively (Figure 2B, overall, _P_=0.472). A similar observation was found by comparing T/S values with tumour grade; T/S values did not differ between well-differentiated (median 0.63,
IQR 0.47–0.97), moderately differentiated (0.67, 0.46–1.02), and poorly differentiated tumours (0.59, 0.45–0.78) (overall, _P_=0.561). The CRCs were then stratified according to p53 and MSI
status: an equal number of MSS tumours had the wild-type (_n_=45) or mutated (_n_=45) _p53_ gene; 24 MSI-H tumours had the wild-type _p53_ gene, whereas four tumours showed the rare pattern
of both MSI-H and the mutated _p53_ gene. Median (IQR) T/S values were 0.65(0.50–0.98) and 0.62(0.43–0.97) in CRCs with the wild-type (_n_=69) and mutated _p53_ gene (_n_=49), respectively,
and 0.66(0.46–1.03) and 0.56(0.43–0.73) in MSS (_n_=90) and MSI-H tumours (_n_=28), respectively (_P_=0.065) (Figures 3A and B). Furthermore, in tumours carrying the wild-type _p53_ gene,
telomeres were significantly shorter in MSI-H (_n_=24) than in MSS cases (_n_=45) (0.56(0.43–0.73) _vs_ 0.70(0.50–1.113), _P_=0.027) (Figure 3C). In MSS tumours, those carrying the mutated
_p53_ gene had shorter telomeres than those carrying the wild-type _p53_ gene, but this difference was not statistically significant (0.62(0.43–0.97) _vs_ 0.70(0.50–1.113), _P_=0.218)
(Figure 3C). Telomere lengths also differed according to tumour location. Median (IQR) T/S values were 0.57 (0.41–0.82), 0.61(0.44–0.98), and 0.78(0.62–1.09) in the 53 right-colon, 30
left-colon, and 35 rectal carcinomas, respectively (overall, _P_=0.03; right colon _vs_ rectum _P_=0.009) (Figure 4). Normal tissues surrounding colon and rectal tumours did not
significantly differ (median (IQR) 1.82 (1.48–2.51), 2.13(1.49–2.86), and 1.87(1.25–2.61) in right-colon, left-colon, and rectal tissues, respectively; _P_=0.81). It can be noted that 49%
(26 of 53) of right-colon tumours but only 3% (2 of 65) of left-colon and rectal cancers showed MSI. The four cases with both MSI and the _p53_-mutated gene were also right-colon cancers. In
contrast, p53 mutation occurred in a higher percentage in left-colon and rectal tumours (60 and 43%, respectively) than in right-colon cancers (23%). With multivariate analyses, telomere
length remained significantly associated with tumour location after adjustment for age and p53 status (_P_=0.04), as well as after adjustment for age and p53/MSI status (_P_=0.05). It is
interesting that even among MSS tumours, right-colon cancers had shorter telomeres than left-colon and rectal cancers (median (IQR) 0.58(0.40–1.05) _vs_ 0.62(0.44–0.98) and 0.80 (0.60–1.20),
respectively; _P_=0.09; right-colon _vs_ rectum _P_=0.047). RELATIONSHIP BETWEEN HTERT EXPRESSION AND TUMOUR CHARACTERISTICS Quantification of TERT transcripts was available for 65 CRC
samples. No relationship was found between hTERT levels and MSI status or tumour location. Indeed, median (IQR) levels of hTERT were 82 (34–294) and 144(65–464) copies in MSI (_n_=13) and
MSS CRCs (_n_=52), respectively (_P_=0.195), and 114(39–360), 172(71–1192), and 85(37–282) copies in right-colon (_n_=22), left-colon (26), and rectal CRCs (_n_=17), respectively
(_P_=0.301). In contrast, hTERT levels significantly varied with tumour progression; median (IQR) hTERT levels were 41(25–183), 82(60–161), 128(72–236), and 660(268–2543) copies in tumour
stages I (_n_=20), II (_n_=13), III (_n_=11), and IV (_n_=21), respectively (_P_<0.0001), and 36(22–240), 102(70–322), and 1854(630–5739) copies in well-differentiated (_n_=14),
moderately differentiated (_n_=41), and poorly differentiated tumours (_n_=7), respectively (_P_<0.0001). No correlation was found between telomere length and hTERT level. DISCUSSION The
role of telomere erosion in colorectal carcinogenesis is still largely undefined. Using a real-time PCR assay, which requires a considerably low quantity of biological samples, we estimated
telomere length in a large number of CRCs and in corresponding adjacent non-cancerous mucosa. For the first time, we determined the relationship between telomere length and tumour
progression and location, as well as its relationship to MSI and p53 mutation status, two markers of major pathways of genetic instability in CRCs. Overall, our results indicated that (i)
telomeres in CRCs were consistently shorter than those of adjacent non-cancerous mucosa, regardless of tumour stage and grade, site, or genetic alterations; (ii) telomeres were shorter in
MSI than in MSS carcinomas, and the difference was significant between MSI and MSS tumours carrying the wild-type _p53_ gene; (iii) regardless of genetic alterations, telomeres were shorter
in tumours arising from the right colon and were longer in rectal cancers. In agreement with previous studies (Hastie et al, 1990; Gertler et al, 2004), we found that telomere length
decreased with ageing in normal mucosa, but not in tumours. It has been proposed that telomere shortening with age may increase the risk of cancer (Blasco, 2005; Risques et al, 2008); this
concept may be supported by our results, as telomere shortening between normal and neoplastic tissues was found to be inversely correlated with age. Although telomere length in somatic cells
primarily reflects cellular proliferation, telomere length in tumour cells reflects the balance between cellular proliferation with telomere loss and telomerase activity with _de novo_
synthesis of telomeric sequences. Evidence that telomeres were shorter in CRCs than in adjacent mucosa, even in well-differentiated tumours, strongly supports the concept that telomere
erosion is a critical initial event in colorectal carcinogenesis. It is likely that stabilisation and maintenance of telomeres, essential to preventing cellular senescence and conferring
unlimited replicative potential, occur after initial extensive cellular proliferation. It is noteworthy that, although several studies agree that there is a shortening of telomeres in
preneoplastic lesions (O'Sullivan et al, 2006; Raynaud et al, 2008), the relationship between telomere length and tumour progression is still controversial (Engelhardt et al, 1997;
Gertler et al, 2004; O'Sullivan et al, 2006). We did not find any relationship between telomere length and tumour progression. In agreement with previous studies (Terrin et al, 2008),
levels of hTERT increased with tumour progression; it is conceivable that telomere length may stabilise with tumour progression because of an increase in telomerase activity compensating for
replicative telomere loss. It should be pointed out that ∼15% of CRCs presented MSI-H, whereas the _p53_ gene is the known major genetic alteration in CRCs with MSS (Kim et al, 2007; Ogino
et al, 2009). A link between telomere shortening and MSI-H has been suggested in a previous study of 55 CRCs; all MSI tumours (_n_=8) but only half of the remaining MSS tumours had shorter
telomeres than those found in adjacent normal mucosa (Takagi et al, 2000). Our study conducted in a larger number of CRCs demonstrated that both MSI-H and MSS tumours had shorter telomeres
than those found in adjacent mucosa and that MSI-H had shorter telomeres than MSS cancers. The MSI pathway involves a failure of the mismatch repair system (Aaltonen et al, 1993), which
maintains genetic stability not only by repairing DNA replication errors but also by preventing chromosomal recombinations; a deficiency of mismatch repair helps cells overcome cellular
crises caused by critical shortening of telomeres (Bechter et al, 2004). Thus, MSI cells may undergo more proliferative cycles and a more pronounced shortening of telomeres before
stabilising than MSS cells. It is of interest that the difference was particularly high and significant when MSI tumours were compared with MSS tumours carrying the wild-type _p53_ gene. It
can be noted that MSS tumours with the mutated _p53_ gene had slightly shorter telomeres than MSS tumours with the wild-type _p53_ gene. In cells with mutated p53, telomeres may protract
their shortening along with cell proliferation, However, p53 is a well-known negative regulator of hTERT promoter, and mutated p53 may also result in hTERT activation (Liu et al, 2004);
thus, stabilisation of telomeres may occur earlier than in MSI tumours. We found that right-colon tumours displayed significantly shorter telomeres than tumours arising from other sites. In
agreement with previous studies (Iacopetta, 2002; Gervaz et al, 2004; Walther et al, 2008), we found that MSI status was strongly associated with tumour origin in the right colon. However,
this association could only partially explain the finding that telomeres were shorter in right-colon cancers, as half of these tumours were MSS. Interestingly, even in MSS tumours, those
arising in the right colon had significantly shorter telomeres than those arising in the rectum. The prognosis of rectal cancers is worse than that of colon cancer and it is currently under
debate whether rectal cancers are actually a distinct entity. Telomere length distinguishes colon from rectal cancers; as telomere lengths of normal tissues surrounding colon and rectal
cancers did not differ, it is likely that the different telomere length in cancers is due to a different kinetics of telomere erosion/stabilisation in colon and rectal carcinogenesis.
Although no association was found between hTERT level and the tumour origin site, earlier activation of hTERT may contribute to these differences between rectal and colon cancers. Future
studies on these aspects may be of help in the design of anti-neoplastic strategies. REFERENCES * Aaltonen LA, Peltomäki P, Leach FS, Sistonen P, Pylkkänen L, Mecklin JP, Järvinen H, Powell
SM, Jen J, Hamilton SR (1993) Clues to the pathogenesis of familial colorectal cancer. _Science_ 260: 812–816 Article CAS PubMed Google Scholar * Artandi SE, DePinho RA (2010) Telomeres
and telomerase in cancer. _Carcinogenesis_ 31: 9–18 Article CAS PubMed Google Scholar * Barault L, Charon-Barra C, Jooste V, de la Vega MF, Martin L, Roignot P, Rat P, Bouvier AM,
Laurent-Puig P, Faivre J, Chapusot C, Piard F (2008) Hypermethylator phenotype in sporadic colon cancer: Study on a population-based series of 582 cases. _Cancer Res_ 68: 8541–8546 Article
CAS PubMed Google Scholar * Bechter OE, Zou Y, Walker W, Wright W, Shay JW (2004) Telomeric recombination in mismatch repair deficient human colon cancer cells after telomerase
inhibition. _Cancer Res_ 64: 3444–34451 Article CAS PubMed Google Scholar * Bertorelle R, Esposito G, Del Mistro A, Belluco C, Nitti D, Lise M, Chieco-Bianchi L (1995) Association of p53
gene and protein alterations with metastases in colorectal cancer. _Am J Surg Pathol_ 19: 463–471 Article CAS PubMed Google Scholar * Blackburn EH, Greider CW, Szostak JW (2006)
Telomeres and telomerase: the path from maize, _Tetrahymena_ and yeast to human cancer and aging. _Nat Med_ 12: 1133–1138 Article CAS PubMed Google Scholar * Blasco MA (2005) Telomeres
and human disease: ageing, cancer and beyond. _Nat Rev Genet_ 6: 611–622 Article CAS PubMed Google Scholar * Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW,
Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava S (1998) A National Cancer Institute Workshop on microsatellite instability for cancer detection and familial predisposition:
development of international criteria for the determination of microsatellite instability in colorectal cancer. _Cancer Res_ 58: 5248–5257 CAS PubMed Google Scholar * Boulay JL, Reuter J,
Ritschard R, Terracciano L, Hermann R, Rochlitz C (1999) Gene dosage by quantitative real-time PCR. _Biotechniques_ 27: 228–230 Article CAS PubMed Google Scholar * Cawthon RM (2002)
Telomere measurement by quantitative PCR. _Nucleic Acids Res_ 30: e47 Article PubMed PubMed Central Google Scholar * Engelhardt M, Drullinsky P, Guillem J, Moore AS (1997) Telomerase and
telomere length in the development and progression of premalignant lesions to colorectal cancer. _Clin Cancer Res_ 3: 1931–1941 CAS PubMed Google Scholar * Garcia-Aranda C, de Juan C,
Diaz-Lopez A, Sanchez-Pernaute A, Torres AJ, Diaz-Rubio E, Balibrea JL, Benito M, Iniesta P (2006) Correlations of telomere length, telomerase activity, and telomeric-repeat binding factor 1
expression in colorectal carcinoma. _Cancer_ 106: 541–551 Article CAS PubMed Google Scholar * Gertler R, Rosenberg R, Stricker D, Friederichs J, Hoos A, Werner M, Ulm K, Holzmann B,
Nekarda H, Siewert JR (2004) Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal carcinoma. _J Clin Oncol_ 22:
807–814 Article Google Scholar * Gervaz P, Bucher P, Morel P (2004) Two colons-two cancers: paradigm shift and clinical implications. _J Surg Oncol_ 88: 261–266 Article PubMed Google
Scholar * Grady WM, Carethers JM (2008) Genomic and epigenetic instability in colorectal cancer pathogenesis. _Gastroenterology_ 135: 1079–1099 Article CAS PubMed Google Scholar *
Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG (2002) _American Joint Committee on Cancer Staging Manual_. 6th edn, Springer: Philadelphia Book Google Scholar * Hackett JA,
Greider CW (2002) Balancing instability: dual roles for telomerase and telomere dysfunction in tumorigenesis. _Oncogene_ 21: 619–626 Article CAS PubMed Google Scholar * Hastie ND,
Dempster M, Dunlop MG, Thompson AM, Green DK, Allshire RC (1990) Telomere reduction in human colorectal carcinoma and with aging. _Nature_ 346: 866–868 Article CAS PubMed Google Scholar
* Hiyama E, Hiyama K (2007) Telomere and telomerase in stem cells. _Br J Cancer_ 96: 1020–1024 Article CAS PubMed PubMed Central Google Scholar * Iacopetta B (2002) Are there two sides
to colorectal cancer? _Int J Cancer_ 101: 403–408 Article CAS PubMed Google Scholar * Katayama S, Shiota G, Oshimura M, Kawasaki H (1999) Clinical usefulness of telomerase activity and
telomere length in the preoperative diagnosis of gastric and colorectal cancer. _J Cancer Res Clin Oncol_ 125: 405–410 Article CAS PubMed Google Scholar * Kim GP, Colangelo LH, Wieand
HS, Paik S, Kirsch IR, Wolmark N, Allegra CJ, National Cancer Institute (2007) Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer
Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. _J Clin Oncol_ 25: 767–772 Article CAS PubMed Google Scholar * Koopman M, Kortman GA, Mekenkamp L,
Ligtenberg MJ, Hoogerbrugge N, Antonini NF, Punt CJ, van Krieken JH (2009) Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. _Br J Cancer_ 100: 266–273
Article CAS PubMed PubMed Central Google Scholar * Li F, Lai M (2009) Colorectal cancer, one entity or three. _J Zhejiang Univ Sci B_ 10: 219–229 Article PubMed PubMed Central Google
Scholar * Liu L, Lai S, Andrews LG, Tollefsbol TO (2004) Genetic and epigenetic modulation of telomerase activity in development and disease. _Gene_ 340: 1–10 Article CAS PubMed Google
Scholar * Meeker AK, Hicks JL, Iacobuzio-Donahue CA, Montgomery EA, Westra WH, Chan TY, Ronnett BM, De Marzo AM (2004) Telomere length abnormalities occur early in the initiation of
epithelial carcinogenesis. _Clin Cancer Res_ 10: 3317–3326 Article CAS PubMed Google Scholar * Nishikura K, Erikson J, Ar-Rushdi A, Huebner K, Croce CM (1985) The translocated c-myc
oncogene of Raji Burkitt lymphoma cells is not expressed in human lymphostoid cells. _Proc Natl Acad Sci USA_ 82: 2900–2904 Article CAS PubMed PubMed Central Google Scholar *
O'Callaghan NJ, Dhillon VS, Thomas P, Fenech M (2008) A quantitative real-time PCR method for absolute telomere length. _Biotecniques_ 44: 807–809 Article CAS Google Scholar *
O'Sullivan J, Risques RA, Mandelson MT, Chen L, Brentnall TA, Bronner MP, Macmillan MP, Feng Z, Siebert JR, Potter JD, Rabinovitch PS (2006) Telomere length in the colon declines with
age: a relation to colorectal cancer? _Cancer Epidemiol Biomarkers Prev_ 15: 573–577 Article CAS PubMed Google Scholar * Ogino S, Goel A (2008) Molecular classification and correlates in
colorectal cancer. _J Mol Diagn_ 10: 13–27 Article CAS PubMed PubMed Central Google Scholar * Ogino S, Nosho K, Irahara N, Shima K, Baba Y, Kirkner GJ, Meyerhardt JA, Fuchs CS (2009)
Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers. _J Clin Oncol_ 27: 4591–4598 Article PubMed
PubMed Central Google Scholar * Perera SA, Maser RS, Xia H, McNamara K, Protopopov A, Chen L, Hezel AF, Kim CF, Bronson RT, Castrillon DH, Chin L, Bardeesy N, Depinho RA, Wong KK (2008)
Telomere dysfunction promotes genome instability and metastatic potential in a K-ras p53 mouse model of lung cancer. _Carcinogenesis_ 29: 747–753 Article CAS PubMed Google Scholar *
Pucciarelli S, Agostini M, Viel A, Bertorelle R, Russo V, Toppan P, Lise M (2003) Early-age at onset colorectal cancer and microsatellite instability as markers of hereditary nonpolyposis
colorectal cancer. _Dis Colon Rectum_ 46: 305–312 Article PubMed Google Scholar * Raynaud CM, Jang SJ, Nuciforo P, Lantuejoul S, Brambilla E, Mounier N, Olaussen KA, André F, Morat L,
Sabatier L, Soria JC (2008) Telomere shortening is correlated with the DNA damage response and telomeric protein down-regulation in colorectal preneoplastic lesions. _Ann Oncol_ 19:
1875–1881 Article CAS PubMed Google Scholar * Risques RA, Lai LA, Brentnall TA, Li L, Feng Z, Gallaher J, Mandelson MT, Potter JD, Bronner MP, Rabinovitch PS (2008) Ulcerative colitis is
a disease of accelerated colon aging: evidence from telomere attrition and DNA damage. _Gastroenterology_ 135: 410–418 Article CAS PubMed Google Scholar * Takagi S, Kinouchi Y,
Hiwatashi N, Chida M, Nagashima F, Takahashi S, Negoro K, Shimosegawa T, Toyota T (1999) Telomere shortening and the clinicopathologic characteristics of human colorectal carcinomas.
_Cancer_ 86: 1431–1436 Article CAS PubMed Google Scholar * Takagi S, Kinouchi Y, Hiwatashi N, Nagashima F, Chida M, Takahashi S, Negoro K, Shimosegawa T, Toyota T (2000) Relationship
between microsatellite instability and telomere shortening in colorectal cancer. _Dis Colon Rectum_ 43: 12–17 Article Google Scholar * Terrin L, Rampazzo E, Pucciarelli S, Agostini M,
Bertorelle R, Esposito G, DelBianco P, Nitti D, De Rossi A (2008) Relationship between tumor and plasma levels of hTERT mRNA in patients with colorectal cancer: implications for monitoring
of neoplastic disease. _Clin Cancer Res_ 14: 7444–7451 Article CAS PubMed Google Scholar * Terrin L, Trentin L, Degan M, Corradini I, Bertorelle R, Carli P, Maschio N, Bo MD, Noventa F,
Gattei V, Semenzato G, De Rossi A (2007) Telomerase expression in B-cell chronic lymphocytic leukemia predicts survival and delineates subgroups of patients with the same IgVH mutation
status and different outcome. _Leukemia_ 21: 965–972 Article CAS PubMed Google Scholar * Walther A, Houlston R, Tomlinson I (2008) Association between chromosomal instability and
prognosis in colorectal cancer: a meta-analysis. _Gut_ 57: 941–950 Article CAS PubMed Google Scholar Download references ACKNOWLEDGEMENTS This work was supported by the Associazione
Italiana per la Ricerca sul Cancro, and by Ministero della Salute ‘Progetto Oncologico di Medicina Molecolare’. RE has a fellowship from the Associazione Italiana per la Ricerca sul Cancro.
We thank Pierantonio Gallo for artwork, and Lisa Smith for editorial assistance. AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of Oncology and Surgical Sciences, Section of
Oncology, University of Padova, Italy E Rampazzo, L Serra, L Terrin & A De Rossi * Istituto Oncologico Veneto-IRCCS, Padova, Italy R Bertorelle, L Terrin, C Candiotto, P Del Bianco &
A De Rossi * Department of Oncology and Surgical Sciences, Section of Surgery, University of Padova, Italy S Pucciarelli & D Nitti Authors * E Rampazzo View author publications You can
also search for this author inPubMed Google Scholar * R Bertorelle View author publications You can also search for this author inPubMed Google Scholar * L Serra View author publications You
can also search for this author inPubMed Google Scholar * L Terrin View author publications You can also search for this author inPubMed Google Scholar * C Candiotto View author
publications You can also search for this author inPubMed Google Scholar * S Pucciarelli View author publications You can also search for this author inPubMed Google Scholar * P Del Bianco
View author publications You can also search for this author inPubMed Google Scholar * D Nitti View author publications You can also search for this author inPubMed Google Scholar * A De
Rossi View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to A De Rossi. ETHICS DECLARATIONS COMPETING INTERESTS The
authors declare no conflict of interest. RIGHTS AND PERMISSIONS This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 License. To view a copy of this
license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Rampazzo, E., Bertorelle, R., Serra, L. _et al._ Relationship
between telomere shortening, genetic instability, and site of tumour origin in colorectal cancers. _Br J Cancer_ 102, 1300–1305 (2010). https://doi.org/10.1038/sj.bjc.6605644 Download
citation * Received: 06 January 2010 * Revised: 10 March 2010 * Accepted: 12 March 2010 * Published: 13 April 2010 * Issue Date: 13 April 2010 * DOI: https://doi.org/10.1038/sj.bjc.6605644
SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to
clipboard Provided by the Springer Nature SharedIt content-sharing initiative KEYWORDS * CRC * genetic instability * telomere